KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Share-based Compensation (2016 - 2025)

Eli Lilly (LLY) has disclosed Share-based Compensation for 17 consecutive years, with $136.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 4.36% year-over-year to $136.1 million, compared with a TTM value of $626.0 million through Dec 2025, down 3.1%, and an annual FY2025 reading of $626.0 million, down 3.1% over the prior year.
  • Share-based Compensation was $136.1 million for Q4 2025 at Eli Lilly, down from $151.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $215.6 million in Q3 2023 and bottomed at $75.3 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $130.7 million, with a median of $132.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 153.35% in 2023, then crashed 38.22% in 2024.
  • Year by year, Share-based Compensation stood at $75.3 million in 2021, then increased by 23.37% to $92.9 million in 2022, then increased by 29.92% to $120.7 million in 2023, then grew by 17.9% to $142.3 million in 2024, then decreased by 4.36% to $136.1 million in 2025.
  • Business Quant data shows Share-based Compensation for LLY at $136.1 million in Q4 2025, $151.1 million in Q3 2025, and $185.1 million in Q2 2025.